Achilles Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Business Highlights
– Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients –
– Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens –
Related news for (ACHL)
- 24/7 Market News- Achilles Therapeutics Discontinues TIL-based cNeT Therapy Development to Focus on Third Party Target
- Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
- Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
- Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference